retrorocket / Shutterstock.com
Hedge fund manager Kyle Bass has filed another petition for an inter partes review (IPR) of a patent covering Horizon Pharma’s arthritis drug Vimovo (naproxen/esomeprazole magnesium).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Kyle Bass, Vimovo, inter partes review, Coalition for Affordable Drugs, Horizon Pharma